Status: retired, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Mar 2022. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3682831017 | Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3682833019 | Glimepiride 2 mg and rosiglitazone maleate 4 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Is a | Product containing glimepiride and rosiglitazone (medicinal product) | false | Inferred relationship | Some | ||
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has active ingredient | Glimepiride (substance) | false | Inferred relationship | Some | ||
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has manufactured dose form | Tablet | false | Inferred relationship | Some | ||
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has active ingredient | Rosiglitazone (substance) | false | Inferred relationship | Some | ||
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has manufactured dose form | Oral tablet | false | Inferred relationship | Some | ||
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has active ingredient | Rosiglitazone maleate | false | Inferred relationship | Some | ||
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Is a | Product manufactured as oral dose form (product) | false | Inferred relationship | Some | ||
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has active ingredient | Glimepiride (substance) | false | Inferred relationship | Some | 1 | |
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has basis of strength substance (attribute) | Glimepiride (substance) | false | Inferred relationship | Some | 1 | |
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has presentation strength numerator value | 2 | false | Inferred relationship | Some | 1 | |
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has presentation strength numerator unit | mg | false | Inferred relationship | Some | 1 | |
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has presentation strength denominator value | 1 | false | Inferred relationship | Some | 1 | |
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | false | Inferred relationship | Some | 1 | |
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has active ingredient | Rosiglitazone maleate | false | Inferred relationship | Some | 2 | |
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has basis of strength substance (attribute) | Rosiglitazone maleate | false | Inferred relationship | Some | 2 | |
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has presentation strength numerator value | 4 | false | Inferred relationship | Some | 2 | |
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has presentation strength numerator unit | mg | false | Inferred relationship | Some | 2 | |
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has presentation strength denominator value | 1 | false | Inferred relationship | Some | 2 | |
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | false | Inferred relationship | Some | 2 | |
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has precise active ingredient | Glimepiride (substance) | false | Inferred relationship | Some | 1 | |
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has precise active ingredient | Rosiglitazone maleate | false | Inferred relationship | Some | 2 | |
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has unit of presentation | Tablet (unit of presentation) | false | Inferred relationship | Some | ||
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Is a | Glimepiride- and rosiglitazone-containing product in oral dose form | false | Inferred relationship | Some | ||
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Count of base of active ingredient | 2 | false | Inferred relationship | Some | ||
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Is a | Glimepiride and rosiglitazone only product in oral dose form | false | Inferred relationship | Some | ||
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has precise active ingredient | Rosiglitazone maleate | false | Inferred relationship | Some | 1 | |
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has basis of strength substance (attribute) | Rosiglitazone maleate | false | Inferred relationship | Some | 1 | |
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has precise active ingredient | Glimepiride (substance) | false | Inferred relationship | Some | 2 | |
| Product containing precisely glimepiride 2 milligram and rosiglitazone maleate 4 milligram/1 each conventional release oral tablet | Has basis of strength substance (attribute) | Glimepiride (substance) | false | Inferred relationship | Some | 2 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets
Concept inactivation indicator reference set
REPLACED BY association reference set (foundation metadata concept)
FHIR